ArticleAntiviral therapy2014
Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study.
Article in Antiviral therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies.International journal of antimicrobial agents · 2018Pooled it
- Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort.Open forum infectious diseases · 2025Article
- Review
- Abacavir antiretroviral therapy and indices of subclinical vascular disease in persons with HIV.PloS one · 2022Article
- Increased endothelial biomarkers are associated with HIV antiretroviral therapy and C-reactive protein among a African rural population in Limpopo Province, South Africa.Frontiers in public health · 2022Article
- HIV-Infected Naïve Patients Exhibit Endothelial Dysfunction Concomitant with Decreased Natural Antibodies Against Defined Apolipoprotein B Autoantigens.Arquivos brasileiros de cardiologia · 2021Article
- Effects of HIV Infection on Arterial Endothelial Function: Results From a Large Pooled Cohort Analysis.Arteriosclerosis, thrombosis, and vascular biology · 2021Article
- Evaluation of Platelet Activation by HIV Protease Inhibitors - The HIV-PLA II Study.HIV/AIDS (Auckland, N.Z.) · 2021Article
- Coronary Microvascular Dysfunction in HIV: A Review.Journal of the American Heart Association · 2020Review
- Current pharmacotherapy for the treatment of dyslipidemia associated with HIV infection.Expert opinion on pharmacotherapy · 2019Review
- Hypertension Risk with Abacavir Use among HIV-Infected Individuals: A Nationwide Cohort Study.Yonsei medical journal · 2018Article
- Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study.BMC infectious diseases · 2017Article
- Brief Report: Should Abacavir Be a First-Line Alternative for Adults With HIV in Sub-Saharan Africa?Journal of acquired immune deficiency syndromes (1999) · 2017Article
- Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.BMC medicine · 2016Observational
- Serum amyloid P (SAP) is associated with impaired brachial artery flow-mediated dilation in chronically HIV-1 infected adults on stable antiretroviral therapy.HIV clinical trials · 2015Article
- Telmisartan to reduce cardiovascular risk in older HIV-infected adults: a pilot study.HIV clinical trials · 2015Article
- Ageing with HIV: a multidisciplinary review.Infection · 2015Review
- The ongoing need for good physiological investigation: obstructive sleep apnea in HIV patients as a paradigm.Journal of applied physiology (Bethesda, Md. : 1985) · 2015Article
- Article
- Management of HIV/AIDS in older patients-drug/drug interactions and adherence to antiretroviral therapy.HIV/AIDS (Auckland, N.Z.) · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 10 institutions in 1 country.
Funding
Abstract
backgroundThe association between abacavir (ABC) and cardiovascular disease (CVD) risk in HIV-infected individuals is unclear. Putative mechanisms for an effect of ABC on CVD risk including endothelial dysfunction have been proposed; however, a biological mechanism has not been established.
methodsThis was a cross-sectional study of HIV-infected subjects with HIV RNA levels <400 copies/ml, who were randomly assigned to ABC or tenofovir (TDF) as initial therapy during a prior clinical trial. A small cohort of subjects on zidovudine (AZT; not randomly assigned) were studied to explore long-term exposure to this agent. All underwent brachial artery ultrasound for flow-mediated dilation (FMD), and D-dimer, high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6) and fasting lipids were measured. Between-arm differences were evaluated by multivariable linear or logistic regression modelling.
resultsThere were 148 subjects (46 on ABC, 72 on TDF and 30 on AZT). Demographic characteristics were balanced across the groups except, as expected, AZT-treated participants were older, had higher CD4(+) T-cell counts, and longer antiretroviral therapy duration. After adjusting for age, brachial artery diameter, and treatment duration, FMD was similar in those on ABC (3.9%) and TDF (5.4%; P=0.181). FMD was higher in those on AZT (6.1%; P<0.005). Levels of IL-6, hsCRP and detectable D-dimer were similar between groups.
conclusionsAmong individuals assigned to ABC or TDF in randomized clinical trials there were no significant differences in FMD or markers of inflammation and coagulation. Whether ABC contributes to risk of CVD remains unclear, but our results suggest that endothelial dysfunction, heightened inflammation, and altered coagulation are unlikely to be mechanisms by which the drug could increase CVD risk above that seen with TDF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.